Variation in Body Weight Increases Risk for Dementia in Adulthood
High body weight variability may be associated with increased risk for all-cause dementia and Alzheimer dementia in older patients.
Dementia
Comorbid Visual Impairment, Dementia Heighten Disability Risk
Older adults with both dementia and self-reported visual impairment may be at higher risk for disability than adults with only one of these conditions.
Relationship Between Serum Uric Acid and Cognitive Function, Dementia
Researchers explored the association between midlife serum uric acid and the risk for cognitive decline and dementia.
Early Metformin Initiation Does Not Appear to Reduce Risk for Dementia
Previous research has suggested that treatment with metformin may potentially lower the risk of dementia, however whether the timing of treatment impacts this result remains unclear.
Benzodiazepines, Z-Drugs Not Associated With Subsequent Dementia Risk
Use of benzodiazepines, Z-drugs, or other anxiolytics was not associated with incident dementia in either the cohort or nested case-control design.
Visual Impairment May Increase Risk for Dementia in Older Women
In older women, objectively measured visual impairment is associated with a twofold to more than fivefold increased risk for dementia.
Daily Low-Dose Aspirin Does Not Cut Dementia Risk in Seniors
Between the aspirin and placebo groups, there was no significant difference in the risk for all dementia triggers, probable Alzheimer disease, or mild cognitive impairment.
Widowhood Tied to More Rapid Cognitive Decline Among Elderly
Rate of cognitive decline was even faster among widowed participants with higher β-amyloid levels at baseline.
Anticholinergic Medications for Overactive Bladder May Increase Risk for Dementia
Among patients with OAB, anticholinergic medication use appears to be associated with an increased risk of new onset dementia when compared with beta-3 agonist use, according to the findings of a retrospective population-based cohort study.
Gene Therapy for Frontotemporal Dementia With a GRN Mutation Gets Fast Track Status
The FDA has granted Fast Track designation to PR006 (Prevail Therapeutics), an experimental gene therapy, to slow the progression of frontotemporal dementia with a GRN mutation.
-
Loading...
-
Loading...
Next post in Alzheimer's Disease and Dementia
